Clinical Trials Browser

Recruiting × Neoplasm, Residual × daratumumab × Clear all

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Phase NA Recruiting

Multiple Myeloma, Neoplasm, Residual